ORKA NASDAQ
Oruka Therapeutics, Inc.
1W: +21.1%
1M: +13.8%
3M: +8.8%
YTD: +238.9%
1Y: +251.6%
3Y: +631.4%
5Y: +441.9%
$95.81
+5.48 (+6.07%)
Pre-Market: $94.25 (-1.56, -1.63%)
Weekly Expected Move ±6.7%
$69
$75
$80
$86
$91
Credit Risk of going bust: lower than 89% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-07-07
Earliest Filing
2025-02-05
Latest Filing
partner: 7
acquirer: 1
target: 1
Counterparties (Filed by ORKA)
9 relationshipsCompanies named in ORKA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Paragon Therapeutics, Inc. | — | partner | Granted Oruka Therapeutics an exclusive license to develop and commercialize antibodies targeting IL-17A/F. | 2025-02-05 | View |
| Paragon Therapeutics, Inc. | — | partner | Granted Oruka Therapeutics an exclusive license to develop and commercialize IL-23 targeting antibodies. | 2024-12-19 | View |
| Genvara Biopharma, Inc. | — | acquirer | Agreed to purchase ARCA's legacy Gencaro and rNAPc2 assets for $300,000 | 2024-08-15 | View |
| Oruka Therapeutics, Inc. | ORKA | partner | Surviving corporation in the First Merger with Merger Sub I | 2024-08-15 | View |
| Oruka Therapeutics, Inc. | ORKA | target | Target company in a merger agreement with ARCA biopharma, Inc. | 2024-04-03 | View |
| Cable Car Capital LLC | — | partner | Entered into a Cooperation Agreement to appoint a director and establish standstill restrictions. | 2022-06-21 | View |
| The Funicular Fund, LP | — | partner | Signatory to the Cooperation Agreement as part of the CCC Group. | 2022-06-21 | View |
| Funicular Funds, LP | — | partner | Signatory to the Cooperation Agreement as part of the CCC Group. | 2022-06-21 | View |
| University Medical Center of Johannes Gutenberg University Mainz | — | partner | Patent assignment agreement for rNAPc2 COVID-19 treatment rights | 2021-07-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-24 | Officer/Director Change; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-04-30 | Earnings Release; Other Events; Exhibits | View | |
| 2026-04-27 | Regulation FD; Other Events; Exhibits | View | |
| 2025-12-11 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-09-22 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-07-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-02-05 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-12-19 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-11-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-11-14 | Other Events; Financial Statements and Exhibits | View | |
| 2024-10-04 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-09-13 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Amendments to Art | Agreement | View |
| 2024-09-05 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Result | Agreement Acquisition | View |
| 2024-08-27 | Other Events; Financial Statements and Exhibits | View | |
| 2024-08-23 | Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR